Monitoring therapeutic efficacy of sunitinib using [<sup>18</sup>F]FDG and [<sup>18</sup>F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma
作者: Benoît ThézéNicholas BernardsAudrey BeynelStephan BouetBertrand KuhnastIrène BuvatBertrand TavitianRaphaël Boisgard
作者单位: 1UMR 1023 Inserm/CEA/Université Paris Sud - ERL 9218 CNRS, CEA/I²BM/SHFJ
2Animal Genetics and Integrative Biology, INRA-AgroParisTech, UMR 1313
3Laboratory of Radiobiology and Genomics Studies, CEA, DSV, IRCM, SREIT
4Inserm U970, Université Paris Descartes
刊名: BMC Cancer, 2015, Vol.15 (1)
来源数据库: Springer Journal
DOI: 10.1186/s12885-015-1540-2
关键词: Breast cancerPyMTSunitinibPETDigital microscopy
英文摘要: Abstract(#br) Background(#br)Clinical studies implying the sunitinib multi-kinase inhibitor have led to disappointing results for breast cancer care but mostly focused on HER2-negative subtypes. Preclinical researches involving this drug mostly concern Triple Negative Breast Cancer (TNBC) murine models. Here, we explored the therapeutic efficacy of sunitinib on a PyMT-derived transplanted model classified as luminal B (HER2-positive) and monitored the response to treatment using both in vivo and ex vivo approaches.(#br) Methods(#br)Tumour-induced animals were treated for 9 ( n = 7) or 14 ( n = 8) days with sunitinib at 40 mg/kg or with vehicle only. Response to therapy was assessed in vivo by monitoring glucose tumour metabolism and hypoxia using 2-deoxy-2-[18F]fluoro-D-glucose...
全文获取路径: PDF下载  Springer  (合作)
影响因子:3.333 (2012)

  • mammary 乳房的
  • therapeutic 治疗的
  • carcinoma 癌症
  • luminal 鲁米那
  • efficacy 效验
  • PET PagE frame Table
  • model 模型